Belite Bio (BLTE) CFO Hao-Yuan Chuang sells 367 ADSs under 10b5-1 plan

Rhea-AI Filing Summary

BELITE BIO, INC director and Chief Financial Officer Hao-Yuan Chuang reported selling a total of 367 American depositary shares of the company on August 12, 2026, in two open-market transactions. Each sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.

Insider Trade Summary 10b5-1

Net Seller: 367 shares

Net Sell 2 txns

Insider Chuang Hao-Yuan

Role Chief Financial Officer

Sold 367 shs ($66K)

Type	Security	Shares	Price	Value
Sale	American depositary share F1, F2	144	$180.00	$26K
Sale	American depositary share F1, F2	223	$180.57	$40K

Holdings After Transaction: American depositary share — 93,433 shares (Direct)

Footnotes (2)

1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/22/2025.

Key Figures

Shares sold (first transaction): 144 American depositary shares Shares sold (second transaction): 223 American depositary shares Total shares sold: 367 American depositary shares +3 more

6 metrics

Shares sold (first transaction) 144 American depositary shares Open-market sale on August 12, 2026 at $180.0000 per share

Shares sold (second transaction) 223 American depositary shares Open-market sale on August 12, 2026 at $180.5700 per share

Total shares sold 367 American depositary shares Aggregate of reported sales; transaction summary netBuySellShares -367

ADS to ordinary share ratio 1 ADS = 1 ordinary share Each American depositary share represents one ordinary share, par value US$0.0001

Par value per ordinary share US$0.0001 per share Par value of the issuer’s ordinary shares represented by each ADS

10b5-1 plan adoption date December 22, 2025 Date the reporting person adopted the Rule 10b5-1 trading plan

Key Terms

American depositary share, Rule 10b5-1 trading plan, Form 4

3 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Form 4 regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transactions did BELITE BIO (BLTE) report for August 12, 2026?

BELITE BIO reported that its CFO and director Hao-Yuan Chuang sold 367 American depositary shares on August 12, 2026 in two open-market transactions at prices around $180 per share.

Who from BELITE BIO (BLTE) sold shares in this Form 4 filing?

The reporting person is Hao-Yuan Chuang, a director and Chief Financial Officer of BELITE BIO, INC, who reported open-market sales of American depositary shares on August 12, 2026.

How many BELITE BIO (BLTE) shares did the CFO sell and at what prices?

The CFO sold 144 ADSs at $180.00 per share and 223 ADSs at $180.57 per share, for a total of 367 American depositary shares in open-market transactions.

Were BELITE BIO (BLTE) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2025, indicating the trades were pre-arranged.

What does each BELITE BIO (BLTE) American depositary share represent?

Each BELITE BIO American depositary share (ADS) represents one ordinary share of the issuer, with a par value of US$0.0001 per share, according to the filing footnote.

Does the Form 4 for BELITE BIO (BLTE) show remaining holdings after the CFO’s sale?

The non-derivative transaction entries report the sales but do not specify total shares following the transactions, leaving the post-transaction holdings amount unspecified in this filing’s data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 06:10 AM Accepted by SEC EDGAR 08/14/2026 - 06:10 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chuang Hao-Yuan

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	08/12/2026		S(2)		144	D	$180	93,656	D
American depositary share(1)	08/12/2026		S(2)		223	D	$180.57	93,433	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/22/2025.

	/s/ Chuang Hao-Yuan	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)